Fate Therapeutics, Inc.
NASDAQ:FATEBiotechnology
-$0.00 today
- Market cap
- $122.39M
- Beta
- 2.52
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.08
Volume 1.87M
Average 2.92M
FATE Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Fate Therapeutics, Inc.NASDAQ: FATE
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity falls 37.7% from a year ago
Total equity stood at $179.71M at the end of Q1 FY2026, down 37.7% from a year earlier and down 13.3% from the prior quarter. Over 3 fiscal years it compounded at -24.6% a year.
Context
- Total equity amounted to 63.1% of total assets at the end of Q1 FY2026, down 9.3 pp from a year earlier.
- Total equity increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps falling in the next quarterly balance sheet after a -37.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 207.18M USD
- Year-over-year change
- -35.0%
- 4-year CAGR
- -25.7%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 207.18M | -35.0% |
| FY2024 | 2024-12-31 | 318.73M | -13.5% |
| FY2023 | 2023-12-31 | 368.42M | -23.9% |
| FY2022 | 2022-12-31 | 483.94M | -28.7% |
| FY2021 | 2021-12-31 | 678.84M | — |
Total Equity vs competitors
How FATE compares with its peers on the latest reported figures
- Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -37.7% is the 4th highest of 10, against a peer median of -43.8%.
- Total equity amounts to 63.1% of total assets for FATE, versus a peer median of 65.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $285.86M USD | -24.5% | -5.7% | 76.8% | |
| Mar 2026 | $179.71M USD | -37.7% | -24.6% | 63.1% | |
| Mar 2026 | $133.98M USD | +45.9% | -6.4% | 85.7% | |
| Mar 2026 | $126.34M USD | -0.6% | +64.7% | 87.4% | |
| Mar 2026 | $87.48M USD | -43.8% | -28.0% | 65.5% | |
| Mar 2026 | CHF 68.25M CHF | -46.8% | -30.1% | 78.1% | |
| Mar 2026 | $60.18M USD | -41.7% | -29.4% | 50.3% | |
| Mar 2026 | $10.38M USD | -89.0% | -47.7% | 4.3% | |
| Mar 2026 | $6.07M USD | -88.2% | -52.3% | 12.2% | |
| Mar 2026 | -$150.42M USD | -327.7% | — | 29.7% | |
| Peer median (excluding FATE) | — | -43.8% | -28.7% | 65.5% | |
Competitors are the stored peer set for FATE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 133.58M | 61.33M | 41.87M | 36.06M | 46.63M |
| Short-term Investments | 482.33M | 374.89M | 273.31M | 243.01M | 157.03M |
| Net Receivables | 8.68M | 38.48M | 1.83M | 3.54M | 916K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 1.1M | 27.37M | 900K | 9.3M | 4.13M |
| Total Current Assets | 633.41M | 502.07M | 331.54M | 291.91M | 208.7M |
| Property, Plant & Equipment (Net) | 162.25M | 66.07M | 158.51M | 110.89M | 98.53M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 100.66M | 4.94M | 980K | 27.66M | 1.47M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 25.13M | 132.48M | 15.19M | 10.24M | 10.23M |
| Total Non-current Assets | 288.04M | 203.49M | 174.68M | 148.79M | 110.23M |
| Total Assets | 921.46M | 705.56M | 506.22M | 440.69M | 318.94M |
| Account Payables | 8.61M | 8.27M | 4.72M | 9.37M | 2.66M |
| Short-term Debt | 0 | 0 | 6.18M | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 21.48M | 42.23M | 685K | 393K | 381K |
| Other Current Liabilities | 3.2M | 40.03M | 16.95M | 11.64M | 8.45M |
| Total Current Liabilities | 81.28M | 114.05M | 39.09M | 38.52M | 36.07M |
| Long-term Debt | 0 | 0 | 0 | 0 | 73.29M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 27.12M | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 24.97M | 3.86M | 1.35M | 5.6M | 2.4M |
| Total Non-current Liabilities | 161.33M | 107.57M | 98.71M | 83.45M | 75.68M |
| Total Liabilities | 242.62M | 221.62M | 137.8M | 121.97M | 111.75M |
| Common Stock | 96K | 97K | 99K | 114K | 115K |
| Retained Earnings | (769.08M) | (1.05B) | (1.21B) | (1.4B) | (1.53B) |
| Accumulated OCI | (762K) | (1.85M) | 15K | 268K | 116K |
| Other Stockholders Equity | 0 | 0 | (0) | 0 | 1.74B |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 678.84M | 483.94M | 368.42M | 318.73M | 207.18M |
| Total Debt | 114.82M | 109.34M | 103.54M | 85.27M | 77.85M |
| Net Debt | (18.77M) | 48.01M | 61.67M | 49.21M | 31.22M |
Fate Therapeutics, Inc.
NASDAQ:FATE
Intrinsic Alpha fair value
Locked
Current Price
$1.05
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.